Ilumya and Taltz Comparison

Ilumya®(tildrakizumab-asmn)	Taltz®(ixekizumab)
Prescription Only Ilumya is a medication used to reduce inflammation associated with psoriasis. It is administered by subcutaneous injection every 12 weeks after an initial loading dose and must be...	Prescription Only Taltz, a monoclonal antibody, has anti-inflammatory properties and can potentially alleviate symptoms of psoriasis, psoriatic arthritis, or ankylosing spondylitis. Its...
Administration
Subcutaneous Injection. Learn more.	Subcutaneous Injection. Learn more.
Dosing
Recommended dose is 100 mg at Weeks 0, 4, and every twelve weeks thereafter.. Learn more.	Recommended dosage is 80 mg by subcutaneous injection every 4 weeks.. Learn more.
Latin Shorthand
100mg Wks 0, 4, then q12w.. Learn more.	80mg SC inj. Q4W. Learn more.
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	$5. Learn more.
Annual Cap
$6,000. Learn more.	$9,100. Learn more.
Assistance Expiration
2 years. Learn more.	12/31/2025 or 36 months from qualification, whichever comes first (with prior authorization and appeal process as required). Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
Most common (≥1%) adverse reactions associated with ILUMYA treatment are upper respiratory infections, injection site reactions, and diarrhea.. Learn more.	Most common (≥1%) adverse reactions associated with TALTZ treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.. Learn more.
Mechanism of Actions (MoA)
Interleukin 23 Antagonist. Learn more.	Interleukin 17A Antagonists. Learn more.
Special Populations
What is the risk of ILUMYA use during pregnancy? Limited available data on the use of ILUMYA during pregnancy are insufficient to inform a drug-associated risk of adverse developmental outcomes. Human IgG is known to cross the placental barrier; therefore, ILUMYA may be transferred from the mother to the fetus. An embryofetal developmental study conducted with tildrakizumab in pregnant monkeys revealed no treatment-related effects to the developing fetus when tildrakizumab was administered subcutaneously during organogenesis to near parturition at doses up to 159 times the maximum recommended human dose (MRHD). When dosing was continued until parturition, a small increase in neonatal death was observed at 59 times the MRHD. What is the background risk of birth defects and miscarriage during pregnancy? All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. What does the animal data on ILUMYA use during pregnancy show? In an embryofetal developmental study, subcutaneous doses up to 300 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks during organogenesis to gestation day 118. No maternal or embryofetal toxicities were observed at doses up to 300 mg/kg. Tildrakizumab crossed the placenta in monkeys. In a pre- and postnatal developmental study, subcutaneous doses up to 100 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks from gestation day 50 to parturition. Neonatal deaths occurred in the offspring of one control monkey, two monkeys at 10 mg/kg dose, and four monkeys at 100 mg/kg dose. The clinical significance of these nonclinical findings is unknown. What is the risk of ILUMYA use during lactation? There are no data on the presence of tildrakizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. Tildrakizumab was detected in the milk of monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ILUMYA and any potential adverse effects on the breastfed child from ILUMYA or from the underlying maternal condition. What is the safety and effectiveness of ILUMYA in pediatric patients? ILUMYA has not been established as safe and effective in pediatric patients under the age of 18. What is the geriatric use of ILUMYA? During Phase 2 and 3 trials, 92 subjects aged 65 or older and 17 subjects aged 75 or older were exposed to ILUMYA 100mg. Although there were no observed differences in safety or efficacy between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects.	What is the Pregnancy Exposure Registry? It is a registry that monitors pregnancy outcomes in women exposed to TALTZ during pregnancy. How can pregnant women enroll in the TALTZ Pregnancy Registry? Pregnant women exposed to TALTZ can enroll in the registry by calling 1-800-284-1695. Contact information for the registry is also available on https://www.taltz.com. What is the risk associated with TALTZ use in pregnant women? Available data from the published literature and the pharmacovigilance database with TALTZ use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Is there a risk of harm to the developing fetus with TALTZ use in pregnant women? An embryofetal development study conducted in pregnant monkeys during organogenesis at doses up to 19 times the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus. When dosing was continued until parturition, neonatal deaths were observed at 1.9 times the MRHD. However, the clinical significance of these nonclinical findings is unknown. What is the background risk of major birth defects and miscarriage in the U.S. general population? The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies in the U.S. general population is 2 to 4% and 15 to 20%, respectively. Is TALTZ present in human milk and what are its effects on breastfed infants? There are no available data on the presence of ixekizumab (TALTZ) in human milk, the effects on the breastfed infant, or the effects on milk production. However, ixekizumab was detected in the milk of lactating cynomolgus monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TALTZ and any potential adverse effects on the breastfed infant from TALTZ or from the underlying maternal condition. Is TALTZ safe and effective for use in pediatric patients? TALTZ is approved for use in pediatric patients aged 6-18 years with moderate-to-severe plaque psoriasis. Its safety and effectiveness have not been established in other pediatric indications or in patients less than 6 years of age.

Ilumya®(tildrakizumab-asmn)

Taltz®(ixekizumab)

Prescription Only

Ilumya is a medication used to reduce inflammation associated with psoriasis. It is administered by subcutaneous injection every 12 weeks after an initial loading dose and must be...

Prescription Only

Taltz, a monoclonal antibody, has anti-inflammatory properties and can potentially alleviate symptoms of psoriasis, psoriatic arthritis, or ankylosing spondylitis. Its...

Dosage & Administration

Administration

Subcutaneous Injection. Learn more.

Dosing

Recommended dose is 100 mg at Weeks 0, 4, and every twelve weeks thereafter.. Learn more.

Recommended dosage is 80 mg by subcutaneous injection every 4 weeks.. Learn more.

Latin Shorthand

100mg Wks 0, 4, then q12w.. Learn more.

80mg SC inj. Q4W. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$0. Learn more.

$5. Learn more.

Annual Cap

$6,000. Learn more.

$9,100. Learn more.

Assistance Expiration

2 years. Learn more.

12/31/2025 or 36 months from qualification, whichever comes first (with prior authorization and appeal process as required). Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

Most common (≥1%) adverse reactions associated with ILUMYA treatment are upper respiratory infections, injection site reactions, and diarrhea.. Learn more.

Most common (≥1%) adverse reactions associated with TALTZ treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.. Learn more.

Mechanism of Actions (MoA)

Interleukin 23 Antagonist. Learn more.

Interleukin 17A Antagonists. Learn more.

Special Populations

What is the risk of ILUMYA use during pregnancy?

Limited available data on the use of ILUMYA during pregnancy are insufficient to inform a drug-associated risk of adverse developmental outcomes. Human IgG is known to cross the placental barrier; therefore, ILUMYA may be transferred from the mother to the fetus. An embryofetal developmental study conducted with tildrakizumab in pregnant monkeys revealed no treatment-related effects to the developing fetus when tildrakizumab was administered subcutaneously during organogenesis to near parturition at doses up to 159 times the maximum recommended human dose (MRHD). When dosing was continued until parturition, a small increase in neonatal death was observed at 59 times the MRHD.

What is the background risk of birth defects and miscarriage during pregnancy?

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

What does the animal data on ILUMYA use during pregnancy show?

In an embryofetal developmental study, subcutaneous doses up to 300 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks during organogenesis to gestation day 118. No maternal or embryofetal toxicities were observed at doses up to 300 mg/kg. Tildrakizumab crossed the placenta in monkeys. In a pre- and postnatal developmental study, subcutaneous doses up to 100 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks from gestation day 50 to parturition. Neonatal deaths occurred in the offspring of one control monkey, two monkeys at 10 mg/kg dose, and four monkeys at 100 mg/kg dose. The clinical significance of these nonclinical findings is unknown.

What is the risk of ILUMYA use during lactation?

There are no data on the presence of tildrakizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. Tildrakizumab was detected in the milk of monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ILUMYA and any potential adverse effects on the breastfed child from ILUMYA or from the underlying maternal condition.

What is the safety and effectiveness of ILUMYA in pediatric patients?

ILUMYA has not been established as safe and effective in pediatric patients under the age of 18.

What is the geriatric use of ILUMYA?

During Phase 2 and 3 trials, 92 subjects aged 65 or older and 17 subjects aged 75 or older were exposed to ILUMYA 100mg. Although there were no observed differences in safety or efficacy between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects.

What is the Pregnancy Exposure Registry?

It is a registry that monitors pregnancy outcomes in women exposed to TALTZ during pregnancy.

How can pregnant women enroll in the TALTZ Pregnancy Registry?

Pregnant women exposed to TALTZ can enroll in the registry by calling 1-800-284-1695. Contact information for the registry is also available on https://www.taltz.com.

What is the risk associated with TALTZ use in pregnant women?

Available data from the published literature and the pharmacovigilance database with TALTZ use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.

Is there a risk of harm to the developing fetus with TALTZ use in pregnant women?

An embryofetal development study conducted in pregnant monkeys during organogenesis at doses up to 19 times the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus. When dosing was continued until parturition, neonatal deaths were observed at 1.9 times the MRHD. However, the clinical significance of these nonclinical findings is unknown.

What is the background risk of major birth defects and miscarriage in the U.S. general population?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies in the U.S. general population is 2 to 4% and 15 to 20%, respectively.

Is TALTZ present in human milk and what are its effects on breastfed infants?

There are no available data on the presence of ixekizumab (TALTZ) in human milk, the effects on the breastfed infant, or the effects on milk production. However, ixekizumab was detected in the milk of lactating cynomolgus monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TALTZ and any potential adverse effects on the breastfed infant from TALTZ or from the underlying maternal condition.

Is TALTZ safe and effective for use in pediatric patients?

TALTZ is approved for use in pediatric patients aged 6-18 years with moderate-to-severe plaque psoriasis. Its safety and effectiveness have not been established in other pediatric indications or in patients less than 6 years of age.

Ilumya® Alternatives